Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan
Anticancer Res. 2022 Feb;42(2):1081-1089. doi: 10.21873/anticanres.15570.
BACKGROUND/AIM: Systemic inflammation responses have been associated with cancer development, progression and metastasis. Little is known about the risk of metastasis based on inflammatory-based scores in patients with osteosarcoma. PATIENTS AND METHODS: A total of 65 osteosarcoma patients without metastasis at presentation were enrolled in this retrospective study. All had been diagnosed histologically, and their laboratory data at the first visit were collected from medical records. The inflammation-based scores, tumor size, location, staging, pathological fracture, treatment methods, follow-up periods, and metastasis-free duration were evaluated. RESULTS: A multivariate Cox regression analysis revealed that a high platelet-lymphocyte ratio (PLR) >116 [hazard ratio (HR)=3.8, 95% confidence interval =1.5-9.3; p<0.01], and neutrophil count (NC) ≤4,030/μl (HR=4.5, 95%CI=1.7-12.3; p<0.01), were independent risk factors significantly associated with metastasis of osteosarcoma patients. CONCLUSION: The combination of a high PLR >116 and NC ≤4,030/μl before treatment was a useful inflammatory-based prognostic indicator for metastasis in patients with osteosarcoma.
背景/目的：全身性炎症反应与癌症的发生、发展和转移有关。目前尚不清楚基于炎症的评分在骨肉瘤患者中转移风险的情况。
患者和方法：本回顾性研究共纳入 65 例初诊时无转移的骨肉瘤患者。所有患者均经组织学诊断，其首次就诊时的实验室数据均从病历中收集。评估了炎症评分、肿瘤大小、位置、分期、病理性骨折、治疗方法、随访时间和无转移持续时间。
结果：多变量 Cox 回归分析显示，高血小板-淋巴细胞比值（PLR）>116（风险比[HR]=3.8，95%置信区间=1.5-9.3；p<0.01）和中性粒细胞计数（NC）≤4,030/μl（HR=4.5，95%CI=1.7-12.3；p<0.01）是骨肉瘤患者转移的独立危险因素。
结论：治疗前高 PLR >116 和 NC ≤4,030/μl 的组合是预测骨肉瘤患者转移的有用炎症预后指标。
World J Surg Oncol. 2016-4-29
World J Surg Oncol. 2020-1-30
Zotero 插件